Loading
Life sciences · Journal article
Oncotarget · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Ryan Brownlee1, Aditya Birla1, Hung Bui1, Raniya Ahmad1, Dongyu Zhang1, Andrew Ji1 and Girindra Raval2 1 The Medical College of Georgia at Augusta University, Augusta, GA 30912, USA 2 Department of Medicine, Division of Hematology and Oncology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA Correspondence to: Ryan Brownlee, email:Rbrownlee@augusta.edu Keywords: F5; PROS1; SERPINC1; lung cancer; thrombophilia Received: November 26, 2025 Accepted: August 05, 2026 Published: November 02, 2026 Copyright: © 2026 Brownlee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Purpose: Thrombophilia genes contribute to tumorigenesis and thrombotic events in lung cancer, yet current treatments do not incorporate gene-specific strategies for F2, F5, PROS1, and SERPINC1. We evaluated survival in lung cancer patients with thrombophilia mutations. Materials and Methods: We queried TCGA-LUAD and TCGA-LUSC for primary lung cancers with F2, F5, PROS1, or SERPINC1 mutations. STAR RNA-seq expression was included in univariate and multivariate Cox models comparing patients with versus without thrombophilia mutations, adjusting for age, race, AJCC stage, primary site, treatment type, laterality, and treatment modalities. Hazard ratios with 95% confidence intervals were calculated. Results: We identified 569 patients with thrombophilia mutations and 850 without. Across all mutations, higher pathologic stage and right-sided tumors were associated with worse survival. F5 mutations were significantly associated with survival in middle-lobe (HR 1.49, p = 0.028), pleural (HR 1.33, p = 0.006), and upper-lobe (HR 1.20, p = 0.025) cancers. SERPINC1 and PROS1 mutations were associated with improved survival in upper-lobe cancers. Among upper-lobe cancers, African American patients with F5 mutations had worse survival by age at diagnosis (HR 1.01, p = 0.015) and race (HR 1.33, p = 0.024). Conclusions: Thrombophilia mutations influence lung cancer survival and may help refine gene-targeted therapies.